

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rekha Bansal
Filing Date : October 19, 2003
For : METHOD OF INHIBITING FACTOR
B-MEDIATED COMPLEMENT
ACTIVATION, AND THE USES
THEREOF
Art Unit : 1644
Examiner : Francois P. Vandervegt
Attorney Docket No. : NMT-8440

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This information disclosure statement is being filed to fulfill the duty of candor and good faith toward the Patent and Trademark Office in accordance with 37 CFR §1.56.

A copy of the PTO Form 1449 has been attached.

NON-PATENT LITERATURE

Acioli, J.M., M. Isobe, and S. Kawasaki, "Early Complement System Activation and Neutrophil priming in acute pancreatitis: Participation of trypsin", *Surgery* 1997. 122(5) pp. 909-917

Arnaout, M.A., "Structure and function of the leukocyte adhesion molecules CD11/CD18". *Blood*, 1990. 75(5): p. 1037-50

Barnum, S.R., et al., "Expression of the complement C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma". *Am J Respir Crit Care Med*, 2001. 164(10 Pt 1): 1841-3.

Basta, M., I. Illa, and M.C. Dalakas, "Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis". *J Neuroimmunol*, 1996. 71(1-2): p. 227-9.

Bellander, B.M., et al., "Complement activation in the human brain after traumatic head injury". *J Neurotrauma*, 2001. 18(12): p. 1295-311.

Belmont, H.M., et al., "Complement activation during systematic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. *Arthritis Rheum*, 1986. 29(9): p. 1085-9.

Bonser, R.S., et al., "Complement activation before, during and after cardiopulmonary bypass". *Eur J Cardiothorac Surg*, 1990. 4(6): p. 291-6

Chenoweth, D.E., "Anaphylatoxin formation in extracorporeal circuits", *Complement*, 1986. 3(3): p. 152-65.

Davis, E.A., et al., "Inhibition of neutrophil adhesion and the membrane attack complex of complement synergistically prolongs cardiac xenograft survival", *J Heart Lung Transplant*, 1995. 14(5): p. 973-80.

del Balzo, U., M.J. Polley, and R. Levi, "Cardiac anaphylaxis. Complement activation as an amplification system". *Circ Res*, 1989. 65(3):p.847-57.

Fung, M., et al., *Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits*. *J Thorac Cardiovasc Surg*, 2001. 122(1): p. 113-22.

Furman, M.I., et al., *Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction*. *J Am Coll Cardiol*, 2001. 38(4): p. 1002-6.

Furman, M.I., et al., *Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease*. *J Am Coll Cardiol*, 1998. 31(2): p. 352-8.

Gerard, N.P. and C. Gerard, *Complement in allergy and asthma*. *Curr Opin Immunol*, 2002. 14(6): p. 705-8.

Gillinov, A.M., et al., *Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass*. *Ann Thorac Surg*, 1993. 55(3): p. 619-24.

Gloor, B., et al., *Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis*. Scand J Gastroenterol, 2003. **38**(10): p. 1078-82.

Gong, J., et al., *Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model*. J Clin Immunol, 1996. **16**(4): p. 222-9.

Grant, E.P., et al., *Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis*. J Exp Med, 2002. **196**(11): p. 1461-71.

Grossklau, C., et al., *Induction of platelet aggregation by the complement-derived peptides C3a and C5a*. Naunyn Schmiedebergs Arch Pharmacol, 1976. **295**(1): p. 71-6.

Gupta-Bansal, R., J.B. Parent, and K.R. Brunden, *Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies*. Mol Immunol, 2000. **37**(5): p. 191-201.

Haeflner-Cavaillon, N., et al., *C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes*. J Immunol, 1987. **139**(3): p. 794-9.
Halstensen TS, Brandtzaeg P., *Local Complement activation in inflammatory bowel disease*, Immunol Res. 1991; 10(3-4): 485-92.

Holmes, J.H.t., et al., *Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes*. Inflamm Res, 2002. **51**(12): p. 579-86.

Hopkins, P., et al., *Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis*. Arthritis Rheum, 1988. **31**(5): p. 632-41.

Horigome, I., et al., *Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases*. Clin Exp Immunol, 1987. **70**(2): p. 417-24.

Howard, R.J., et al., *Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation*. Arch Surg, 1988. **123**(12): p. 1496-501.

Humbles, A.A., et al., *A role for the C3a anaphylatoxin receptor in the effector phase of asthma*. Nature, 2000. **406**(6799): p. 998-1001.

Johnson, L.V., et al., *Complement activation and inflammatory processes in Drusen formation and age related macular degeneration*. Exp Eye Res, 2001. **73**(6): p. 887-96.

Kaczorowski, S.L., et al., *Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats*. J Cereb Blood Flow Metab, 1995. **15**(5): p. 860-4.

Kirschfink, M., et al., *[Significance of the complement system for xenotransplantation: strategies for therapeutic intervention]*. Zentralbl Chir, 1998. **123**(7): p. 793-7.

Krug, N., et al., *Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma*. Am J Respir Crit Care Med, 2001. **164**(10 Pt 1): p. 1841-3.

Langlois, P.F. and M.S. Gawryl, *Detection of the terminal complement complex in patient plasma following acute myocardial infarction*. Atherosclerosis, 1988. **70**(1-2): p. 95-105.

Lien, Y.H., L.W. Lai, and A.L. Silva, *Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice*. Life Sci, 2003. **74**(5): p. 543-52.

Lin F. et al., *Decay-Accelerating Factor Deficiency Increases Susceptibility to Dextran Sulfate Sodium-Induced Colitis: Role for Complement in Inflammatory Bowel Disease*, Journal of Immunology 2004, 172:3836-3841

Mead, R.J., et al., *The membrane attack complex of complement causes severe demyelination associated with acute axonal injury*. J Immunol, 2002. **168**(1): p. 458-65.

Meuer, S., et al., *Platelet-serotonin release by C3a and C5a: two independent pathways of activation*. J Immunol, 1981. **126**(4): p. 1506-9.

Mohr, R., et al., *The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations*. J Thorac Cardiovasc Surg, 1988. **96**(4): p. 530-4.

Mullins, R.F., N. Aptsiauri, and G.S. Hageman, *Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis*. Eye, 2001. **15**(Pt 3): p. 390-5.

Nataf, S., et al., *Attenuation of experimental autoimmune demyelination in complement-deficient mice*. J Immunol, 2000. **165**(10): p. 5867-73.

Pruitt, S.K., et al., *The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts*. Transplantation, 1994. **57**(3): p. 363-70.

Rinder, C.S., et al., *Cardiopulmonary bypass induces leukocyte-platelet adhesion*. Blood, 1992. **79**(5): p. 1201-5.

Rinder, C.S., et al., *Role of C3 cleavage in monocyte activation during extracorporeal circulation*. Circulation, 1999. **100**(5): p. 553-8.

Rinder, C.S., et al., *Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation*. J Clin Invest, 1995. **96**(3): p. 1564-72.

Roxvall, L., A. Bengtson, and M. Heideman, *Anaphylatoxin generation in acute pancreatitis*. J Surg Res, 1989. **47**(2): p. 138-43.

Roxvall, L.I., L.A. Bengtson, and J.M. Heideman, *Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and ascites fluid of patients with acute pancreatitis*. Arch Surg, 1990. **125**(7): p. 918-21.

Saatvedt, K., et al., *Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children*. Scand J Clin Lab Invest, 1995. **55**(1): p. 79-86.

Schmid, E., et al., *Requirement for C5a in lung vascular injury following thermal trauma to rat skin*. Shock, 1997. **8**(2): p. 119-24.

Simpson, P.J., et al., *Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion*. J Clin Invest, 1988. **81**(2): p. 624-9.

Stahel, P.F., M.C. Morganti-Kossmann, and T. Kossmann, *The role of the complement system in traumatic brain injury*. Brain Res Brain Res Rev, 1998. **27**(3): p. 243-56.

Stahl, G.L., et al., *Role for the alternative complement pathway in ischemia/reperfusion injury*. Am J Pathol, 2003. **162**(2): p. 449-55.

Thurman, J.M., et al., *Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice*. J Immunol, 2003. **170**(3): p. 1517-23.

Torzewski, J., et al., *Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation*. Arterioscler Thromb Vasc Biol, 1996. **16**(5): p. 673-7.

Undar, A., et al., *Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass*. Ann Thorac Surg, 2002. **74**(2): p. 355-62; discussion 362.

van Beek, J., K. Elward, and P. Gasque, *Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection*. Ann N Y Acad Sci, 2003. **992**: p. 56-71.

Vedeler, C.A., et al., *Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barre syndrome and multiple sclerosis*. J Neuroimmunol, 1996. **67**(1): p. 17-20.

Vickers, J., et al., *Measurement of platelet activation and adhesion to leukocytes during haemodialysis*. Platelets, 1998. **9**(3-4): p. 261-4.

Wan, K.C., et al., *A longitudinal study of C3, C3d and factor Ba in burn patients in Hong Kong Chinese*. Burns, 1998. **24**(3): p. 241-4.

Wang, Y., et al., *Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease*. Proc Natl Acad Sci U S A, 1995. **92**(19): p. 8955-9.

Ware, L.B. and M.A. Matthay, *The acute respiratory distress syndrome*. N Engl J Med, 2000. **342**(18): p. 1334-49.

Yasuda, M., et al., *The complement system in ischemic heart disease*. Circulation, 1990. **81**(1): p. 156-63.

Zhou, W., et al., *Predominant role for C5b-9 in renal ischemia/reperfusion injury*. J Clin Invest, 2000. **105**(10): p. 1363-71.

Ahlgren, E., et al., *Neurocognitive impairment and driving performance after coronary artery bypass surgery*. Eur J Cardiothorac Surg, 2003. **23**(3): p. 334-40.

Ann Thorac Surg. 1994 Mar;57(3):781-3, P.C.a.a.C.a.c.d.c.b.M.P., Chello M, Marchese AR.).

Arrowsmith, J.E., et al., *Central nervous system complications of cardiac surgery*. Br J Anaesth, 2000. **84**(3): p. 378-93.

Cecic, I., J. Sun, and M. Korbelik, *Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells*. Photochem Photobiol, 2006. **82**(2): p. 558-62.

Keith, J.R., et al., *Assessing postoperative cognitive change after cardiopulmonary bypass surgery*. Neuropsychology, 2002. **16**(3): p. 411-21.

Larsson, R., et al., *Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface*. Immunopharmacology, 1997. **38**(1-2): p. 119-27.

Levy, J.H. and K.A. Tanaka, *Inflammatory response to cardiopulmonary bypass*. Ann Thorac Surg, 2003. **75**(2): p. S715-20.

Mahanna, E.P., et al., *Defining neuropsychological dysfunction after coronary artery bypass grafting*. Ann Thorac Surg, 1996. **61**(5): p. 1342-7.

Neumann, E., et al., *Local production of complement proteins in rheumatoid arthritis synovium*. Arthritis Rheum, 2002. **46**(4): p. 934-45.

Newman, M.F., Kirchner J.L., Phillips-Bute B., *Longitudinal assessment of neurocognitive function after coronary artery bypass surgery*. N Engl J Med, 2001. **344**: p. 395-402.

Nilsson B, L.R., Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD., *Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.*, Blood. 1998 Sep 1;92(5):1661-7.

Rinder, C.S., et al., *Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation*. J Thorac Cardiovasc Surg, 1999. **118**(3): p. 460-6.

Selnes, O.A. and G.M. McKhann, *Neurocognitive complications after coronary artery bypass surgery*. Ann Neurol, 2005. **57**(5): p. 615-21.

Selnes, O.A., et al., *Cognitive and neurobehavioral dysfunction after cardiac bypass procedures*. Neurol Clin, 2006. **24**(1): p. 133-45.

Respectfully submitted,

/Richard A. Sutkus/

Richard A. Sutkus

Reg. No. 43,941

TAROLLI, SUNDHEIM, COVELL,
& TUMMINO L.L.P.
1300 East Ninth Street, Suite 1700
Cleveland, Ohio 44114
Phone:(216) 621-2234
Fax: (216) 621-4072
Customer No.: 26,294